# US 6,730,307 B2 · Anti-cryptosporidium parvum preparations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,307 B2
- Document ID: US6730307B2
- Status: Granted
- Kind: B2
- Application number: 09/832,888
- Filed: 2001-04-12
- Published: 2001-10-11
- Granted: 2004-05-04
- Earliest claimed: 1996-03-29
- Assignees: The Arizona Board of Regents Acting on Behalf of the University of Arizona; North Carolina State University
- Inventors: Michael W. Riggs; Lance E. Perryman
- Web page: https://patentgrep.com/patent/US6730307B2

## CPC

- C07K 14/44: from protozoa
- C07K 16/20: from protozoa
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y10S 424/807: Monoclonal
- Y10S 435/947: using protozoa
- Y10S 530/822: Protozoa
- Y10S 530/832: Milk; colostrum
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Compositions and methods useful for conferring passive or active immunity to the parasite, C. parvum. A high molecular weight glycoprotein antigen isolated from C. parvum, capable of binding the mAb 3E2, was shown to harbor an epitope critical for triggering the neutralizing CSP-like reaction in the parasite. Antibodies targeted against the critical epitope were shown to possess neutralizing activity, and could be combined with other anti-C. parvum monoclonal antibodies and administered to an animal to confer passive immunity. Immunogenic compositions including the purified antigen are disclosed for use in stimulating an active immune response against C. parvum.

## Claims

### Claim 1

An isolated antigen of Cryptosporidium parvum comprising a glycoprotein of approximately 1,400 kDa, as measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis, said antigen having disposed thereon an epitope specifically recognizable by monoclonal antibody 3E2, secreted by a hybridoma deposited as accession number ATCC HB 12075, wherein the antigen is present in unisolated form in dense granules in sporozoites.

### Claim 2 (depends on 1)

An immunogenic composition comprising the antigen of claim 1.

### Claim 3 (depends on 2)

The immunogenic composition of claim 2, further comprising an adjuvant.

### Claim 4

An immunogenic composition comprising a substantially purified Cryptosporidium parvum antigen comprising a glycoprotein of approximately 1,400 kDa, as measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis, wherein said antigen is specifically recognizable by monoclonal antibody 3E2, secreted by a hybridoma deposited as accession number ATCC HB 12075, in a pharmaceutically acceptable carrier.

### Claim 5 (depends on 4)

The immunogenic composition of claim 4, further comprising an adjuvant.

### Claim 6

A method of stimulating an anti-Cryptosporidium parvum immune response in a mammal comprising administering to the mammal an immunogenic composition comprising a substantially purified Cryptosporidium parvum antigen specifically recognizable by monoclonal antibody 3E2, secreted by a hybridoma deposited as accession number ATCC HB 12075, in a pharmaceutically acceptable carrier, wherein said antigen is a glycoprotein of approximately 1,400 kDa, as measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis.

### Claim 7 (depends on 6)

The method of claim 6, wherein said stimulating produces an immune serum or colostrum comprising antibodies having an epitope specificity of the monoclonal antibody 3E2, accession number ATCC HB 12075.

### Claim 8 (depends on 7)

The method of claim 7, comprising passively immunizing a second mammal of a same or different species with the immune serum or colostrum.

### Claim 9 (depends on 8)

The method of claim 8, wherein the second mammal is a human being.
